Products Dactinomycin was commercially available as a lyophilizate (Cosmegen). It was approved in many countries since 1966 and was withdrawn from the market in 2012 on November 30 for commercial reasons. It can be imported from abroad if needed. Structure and properties Dactinomycin (C62H86N12O16, Mr = 1255.4 g/mol) is an actinomycin and phenoxazone derivative formed … Dactinomycin
Products Ixabepilone is commercially available as an infusion preparation (Ixempra). It has been approved in many countries since 2009. Effects Ixabepilone (ATC L01DC04) has cytostatic and antitumor properties. Indications Breast cancer
Products Nelarabine is commercially available as a solution for injection (Atriance). It has been approved in many countries since 2007. Structure and properties Nelarabine (C11H15N5O5, Mr = 297.3 g/mol) is a purine analog. Effects Nelarabine (ATC L01BB07) has cytotoxic properties. The effects are due to inhibition of DNA synthesis. Indications Treatment of patients with T-cell … Nelarabine
Products Trastuzumab emtansine is commercially available as a sterile powder for the preparation of an infusion solution concentrate (Kadcyla). It has been approved in many countries since 2013. Structure and properties Trastuzumab emtansine is an antibody-drug conjugate that targets HER2. It consists of the anti-HER2 antibody trastuzumab (Herceptin), which is also linked via a linker … Trastuzumab Emtansine
Products Lomustine was commercially available in the form of capsules (Ceenu). It had been approved in many countries since 1981. Structure and properties Lomustine (C9H16ClN3O2, Mr = 233.7 g/mol) is a yellow crystalline powder that is practically insoluble in water. It is an N-nitrosourea. Effects Lomustine (ATC L01AD02) is alkylating and cytostatic. Indications Brain tumors … Lomustine
Structure and properties Etoposide (C29H32O13, Mr = 588.6 g/mol) is a derivative of podophyllotoxin. It exists as a white crystalline powder that is practically insoluble in water. The substance is weakly hygroscopic. Effects Etoposide (ATC L01CB01) is cytostatic. It inhibits topoisomerase II and blocks the cell cycle at stage G2. Indications Acute myeloid leukemia Hodgkin’s … Etoposide
Products Dacarbazine is commercially available as a lyophilizate in lancing ampoules (Dacin). It has been approved in many countries since 2004. Structure and properties Dacarbazine (C6H10N6O, Mr = 182.2 g/mol) is present as a colorless to ivory colored substance. It is an imidazole carboxamide derivative. Dacarbazine is a prodrug that is biotransformed in the body … Dacarbazine
Products Cytarabine is commercially available as an injectable. It has been approved in many countries since 1971. Structure and properties Cytarabine (C9H13N3O5, Mr = 243.2 g/mol) exists as a white crystalline powder that is readily soluble in water. It is a synthetic pyrimidine. Effects Cytarabine (ATC L01BC01) has cytotoxic properties. It is a pyrimidine antagonist. … Cytarabine
Products Raltitrexed is commercially available as a powder for the preparation of an infusion solution (Tomudex). It was approved in many countries in 1998. Structure and properties Raltitrexed (C21H22N4O6S, Mr = 458.5 g/mol) is an analog of folic acid. Effects Raltitrexed (ATC L01BA03) has cytotoxic properties. The effects are due to selective inhibition of the … Raltitrexed
Products Podophyllotoxin is commercially available as a liniment for external use (Condyline). It has been approved in many countries since 1987. Effects Podophyllotoxin (ATC D06BB04) has cytostatic properties by inhibiting mitosis. Stem plant May apple. Indications Anogenital warts: condylomata acuminata (genital warts).
Products Brentuximab vedotin is commercially available as a powder for the preparation of an infusion solution (Adcetris). It has been approved in many countries since 2013. Structure and properties Brentuximab vedotin is an anti-CD30 antibody-drug conjugate, a recombinant chimeric lgG1 antibody conjugated to the cytotoxic agent monomethylauristatin E (MMAE, C39H67N5O7, Mr = 718.0 g/mol). It … Brentuximab Vedotin
Products Gemtuzumab ozogamicin is approved as a powder for a concentrate for the preparation of an infusion solution (Mylotarg). It was approved in the United States in 2017, in the EU in 2018, and in many countries in 2019 It was previously marketed in the United States between 2000 and 2010 but was withdrawn from … Gemtuzumab Ozogamicin
